Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus HN001 and Reduced Eczema Prevalence

Research synthesisLow evidenceMixed effect size3 studies · 1 beneficial · 2 neutral · 0 harmful

Across 3 randomized controlled trials, only 1 reported a beneficial large-sized effect of Lactobacillus rhamnosus HN001 on reducing eczema prevalence, while 2 found neutral small-sized effects. The most-studied dose is 6 × 10^9 CFU daily, and the mixed populations include pregnant and breastfeeding mothers and their infants. Evidence base is too small to characterize a predominant effect.

  • Effective dose range: 6 × 10^9 CFU daily
  • Studied populations: Pregnant and breastfeeding mothers and their children; high-risk birth cohort

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests. Benefit was observed in one trial where both mothers and infants were supplemented from late pregnancy through age 2 years, whereas maternal-only supplementation showed no effect, suggesting administration timing and duration may be critical.

Generated Jun 12, 2026
Doses used in studies
  • CFU/day: 6 billion (median 6 billion, IQR 6 billion–6 billion) — 3 studies
Safety in these studies
3 of 3 papers
Back to top